Submission of Audited Financial Results along with Auditors Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Pharmaids Pharmaceuticals reported audited results for FY26 ending March 31, 2026. On a consolidated basis, revenue grew 43% to Rs. 2,788.24 Lacs from Rs. 1,944.74 Lacs in FY25. However, the company continues to incur losses with PAT of Rs. (1,157.19) Lacs compared to Rs. (1,350.51) Lacs in FY25, showing a 14% reduction in losses. The standalone entity showed even stronger revenue growth of 353% to Rs. 1,060.25 Lacs, but losses widened to Rs. (1,043.72) Lacs from Rs. (727.92) Lacs. Operating cash flows remain negative at Rs. (405.72) Lacs on consolidated basis. The Board also approved a Rs. 75 Lakh corporate guarantee for subsidiary Adita Bio Sys Private Limited under ECLGS 5.0. Auditors issued unmodified opinions with no qualifications.
The company shows strong revenue growth but remains deeply unprofitable with negative cash flows. Shareholders should monitor whether the company can achieve profitability as it scales operations. The corporate guarantee to the subsidiary adds contingent liability exposure.